- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT05363722
Clinical Study on Efficacy and Safety of IBI310, Bevacizumab Combined With Sintilimab in Advanced HCC
A Single-Arm, Multicenter Phase Ib Study on the Efficacy and Safety of IBI310 in Combination With Bevacizumab and Sintilimab for First-Line Treatment of Advanced Hepatocellular Carcinoma
This is a single-arm, multicenter phase Ib study to evaluate the effectiveness and safety of IBI310, bevacizumab combined with sintilimab in patients with locally advanced or metastatic HCC who have not previously received systemic therapy, are unsuitable for radical surgical resection or local treatment, or have progressive disease after surgical resection or local treatment.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
This is a single-arm, multicenter phase Ib study evaluating the safety and efficacy of IBI310 combined with sintilimab and bevacizumab in advanced hepatocellular carcinoma. Patients will receive IBI310 1.0 mg/kg IV on day 1 every 6 weeks plus sintilimab 200 mg IV and bevacizumab 15 mg/kg IV on day 1 every 3 weeks. Approximately 50 patients are planned. After the first 6-10 patients are treated, the Safety Monitoring Committee (SMC) will assess safety in this subgroup and determine whether enrollment should continue.
Treatment will continue until disease progression, intolerable toxicity, initiation of new antitumor therapy, withdrawal of informed consent, loss to follow-up, death, or other protocol-defined discontinuation, whichever occurs first, for a maximum of 24 months. Patients with initial investigator-assessed radiographic progression per RECIST v1.1 may continue study treatment if clinically stable, likely to benefit, and willing to continue; tumor response will then be assessed by iRECIST until no further benefit per investigator, intolerable toxicity, new antitumor therapy, consent withdrawal, loss to follow-up, or maximum treatment duration, whichever occurs first.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Fase 1
Contactos e Locais
Contato de estudo
- Nome: Chengfeng Liu
- Número de telefone: +86 15201927474
- E-mail: liu.chengfeng@zs-hospital.sh.cn
Locais de estudo
-
-
-
Shanghai, China
- Recrutamento
- Zhongshan Hospital, Fudan University
-
Contato:
- Chengfeng Liu
- Número de telefone: +86 15201927474
- E-mail: liu.chengfeng@zs-hospital.sh.cn
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Histologically/cytologically confirmed hepatocellular carcinoma, or meeting the clinical diagnostic criteria for hepatocellular carcinoma ;
- Aged ≥18 years,≤75 years;
- ECOG performance status score of 0 or 1 point;
- Barcelona Clinic Liver Cancer (BCLC) stage C, or Stage B not suitable for radical surgery and/or local treatment;
- No systemic antitumor treatment for hepatocellular carcinoma before the first administration;
- At least 1 measurable lesion according to the Response Evaluation Criteria in Solid Tumors Version 1.1(RECIST V1.1), or measurable lesion with definite progression after local treatment (based on RECIST V1.1 criteria), at least 4 weeks before enrollment (for those who received local radioisotope therapy, at least 3 months)
- Child-Pugh Class A or B(≤7);
- Adequate organ and bone marrow function.
- Expected life time is over 12 weeks.
- Take effective contraceptive measures
- Willing to attend the study and having given the ICF
Exclusion Criteria:
- Known fibrolamellar HCC, sarcomatoid HCC, mixed cholangiocarcinoma and HCC
- History of hepatic encephalopathy or liver transplantation
- Pleural, ascites, and pericardial effusion with clinical symptoms requiring drainage
- HBV-DNA>2000 IU/ML or 10^4 copies/ml;Untreated positive HCV-RNA;HbsAg and anti-HCV antibody were both positive
- History of GI bleeding within 6 months, or severe (G3) varices at endoscopy within 3 months
- Arteriovenous embolism within 6 months
- The tumor thrombus involved both main and branch portal veins, main portal veins and mesenteric veins or inferior vena cava.
- Antiplatelet drugs were administered for 10 days for therapeutic purposes 2 weeks before administration
- Uncontrolled hypertension
- Unrecovered AE(>CTCAE grade 1) due to previous treatment
- Heart failure (NYHA Classification III-IV), or poorly controlled arrhythmias
- History of gastrointestinal perforation, fistula, intestinal obstruction, extensive bowel resection, Crohn's disease, ulcerative colitis, or chronic diarrhea
- With lung fibrosis, interstitial lung disease, pneumoconiosis, drug-associated pneumonia and serious impairment in lung function
- Active tuberculosis
- Infected with HIV or syphilis
- Severe infections that are active or clinically poorly controlled
- Use of immunosuppressive drugs within 4 weeks prior to initial dosing
- Receipt of live attenuated vaccine within 4 weeks prior to randomization
- Significant traumatic injury or major surgical procedure within 28 days prior to randomization
- Other conditions that the investigator judged inappropriate for inclusion
- Prior immunotherapy or targeted therapy
- Treatment of Traditional Chinese medicine with anti-tumor indications or drugs with immunomodulatory effects whitin 2 weeks
- Pregnant or breast-feeding women
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Single-Arm
IBI310 1mg/kg IV d1 Q6W, sintilimab 200mg IV d1 Q3W, combined with bevacizumab 15mg/kg IV d1,Q3W |
IBI310 1mg/kg IV d1 Q6W sintilimab 200 mg IV d1 Q3W
Outros nomes:
bevacizumab 15 mg/kg IV d1,Q3W
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Treatment Emergent Adverse Event, TEAE
Prazo: Any emergent adverse event from first dose through study completion, up to 2 years.
|
Safety |
Any emergent adverse event from first dose through study completion, up to 2 years.
|
|
Severe Adverse Event, SAE
Prazo: Any severe adverse event from first dose through study completion, up to 2 years.
|
Safety |
Any severe adverse event from first dose through study completion, up to 2 years.
|
|
Objective response rate (ORR)
Prazo: The proportion of patients with complete response or partial response, through study completion, up to 2 years
|
efficacy |
The proportion of patients with complete response or partial response, through study completion, up to 2 years
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Duration of Response(DOR)according to RECIST V1.1 criteria
Prazo: From the date of first documented response(CR/PR) until the date of progression or death, up to 48 months
|
efficacy |
From the date of first documented response(CR/PR) until the date of progression or death, up to 48 months
|
|
Duration of Response(DOR)according to mRECIST criteria
Prazo: From the date of first documented response(CR/PR) until the date of progression or death, up to 48 months
|
efficacy |
From the date of first documented response(CR/PR) until the date of progression or death, up to 48 months
|
|
Disease Control Rate(DCR) according to RECIST V1.1 criteria
Prazo: The percentage of patients whose therapeutic intervention has led to a complete response, partial response, or stable disease, through study completion, up to 2 years
|
efficacy |
The percentage of patients whose therapeutic intervention has led to a complete response, partial response, or stable disease, through study completion, up to 2 years
|
|
Disease Control Rate(DCR) according to mRECIST criteria
Prazo: The percentage of patients whose therapeutic intervention has led to a complete response, partial response, or stable disease, through study completion, up tp 2 years
|
efficacy |
The percentage of patients whose therapeutic intervention has led to a complete response, partial response, or stable disease, through study completion, up tp 2 years
|
|
Objective response rate (ORR) according to mRECIST criteria
Prazo: The proportion of patients with complete response or partial response, through study completion, an average of 2 years
|
efficacy |
The proportion of patients with complete response or partial response, through study completion, an average of 2 years
|
|
Progresison Free Survival(PFS)according to RECIST V1.1 criteria
Prazo: From date of randomization until the date of the first documented progression or date of death from any cause, whichever comes first, assessed up to 48 months
|
efficacy |
From date of randomization until the date of the first documented progression or date of death from any cause, whichever comes first, assessed up to 48 months
|
|
Progresison Free Survival(PFS)according to mRECIST criteria
Prazo: From date of randomization until the date of the first documented progression or date of death from any cause, whichever comes first, assessed up to 48 months
|
efficacy |
From date of randomization until the date of the first documented progression or date of death from any cause, whichever comes first, assessed up to 48 months
|
|
Overall survival (OS)
Prazo: From the date of randomization until death from any cause, assessed up to 48 months.
|
efficacy |
From the date of randomization until death from any cause, assessed up to 48 months.
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Zhenggang Ren, Shanghai Zhongshan Hospital
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
- Neoplasias por local
- Neoplasias
- Neoplasias por Tipo Histológico
- Neoplasias do Aparelho Digestivo
- Doenças do aparelho digestivo
- Doenças do Fígado
- Neoplasias Glandulares e Epiteliais
- Adenocarcinoma
- Neoplasias Hepáticas
- Carcinoma
- Carcinoma Hepatocelular
- Aminoácidos, peptídeos e proteínas
- Proteínas
- Anticorpos, monoclonais, humanizados
- Anticorpos, monoclonais
- Anticorpos
- Imunoglobulinas
- Imunoproteínas
- Proteínas sanguíneas
- Globulinas de soro
- Globulins
- Bevacizumabe
- Sintilimab
Outros números de identificação do estudo
- CIBI310Y001
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .